SEEGNAL INC. ANNOUNCES FILING OF 2025 ANNUAL FILINGS AND THAT THE MCTO WILL NO LONGER BE IN EFFECT AS OF MAY 16, 2026

Why It Matters

Lifting the MCTO signals regulatory compliance and restores executive trading flexibility, bolstering investor confidence. It underscores Seegnal’s momentum in the fast‑growing precision‑medicine market.

Key Takeaways

• MCTO lifted; CEO and CFO can now trade shares.
• Audited 2025 financials filed, meeting continuous disclosure obligations.
• Seegnal’s platform reduces clinician alert load by over 90%.
• System used by 10,000+ Israeli clinicians; expanding to US, UK, UAE, Poland.
• Precision alerts achieve up to 98% accuracy, improving patient safety.

Pulse Analysis

Seegnal Inc. announced that the management cease‑trade order imposed by the Alberta Securities Commission has been terminated as of May 16, 2026. The order, which restricted only the chief executive officer and chief financial officer from trading the company’s shares, was lifted after the firm filed its audited 2025 financial statements and reaffirmed compliance with continuous disclosure rules. By removing this regulatory hurdle, Seegnal restores full trading flexibility for its top executives, a move that typically reassures investors and can improve market liquidity for the TSXV‑listed stock.

The company’s core offering, Seegnal eHealth, is a SaaS‑based clinical decision‑support platform that aggregates patient‑specific data—genetics, labs, ECG, allergies, medication history—and delivers precision drug‑interaction alerts. By filtering out low‑value warnings, the system cuts the traditional alert burden by more than 90 %, allowing clinicians to maintain workflow efficiency while preserving safety. Reported alert accuracy of up to 98 % translates into fewer adverse drug events, reduced hospital admissions, and measurable time savings in prescription renewals, positioning the technology as a high‑impact tool for modern healthcare providers.

Seegnal’s platform is already the standard of care for over 10,000 clinicians in Israel, where the Ministry of Health has adopted its patient‑specific standard across governmental hospitals. The firm is actively expanding into the United Arab Emirates, United Kingdom, United States, and Poland, targeting markets that are increasingly prioritizing precision medicine and medication safety. As payers and providers seek to curb rising drug‑related costs, Seegnal’s ability to lower adverse events and streamline prescribing could drive significant adoption, making it a compelling candidate for strategic partnerships or future public offerings.